| Literature DB >> 30655682 |
Jin Woong Suh1, Yongguk Ju2, Chang Kyu Lee3, Jang Wook Sohn1,2, Min Ja Kim1,2, Young Kyung Yoon1,2.
Abstract
PURPOSE: This study investigated the clinical epidemiology, antimicrobial susceptibility, and molecular epidemiology of Corynebacterium striatum isolates. PATIENTS AND METHODS: An observational study was conducted at a university hospital in the Republic of Korea from August to December 2016. All subjects were patients who tested positive for C. striatum clinically. Clinical data were analyzed to evaluate the microbiological and genotypic characteristics of C. striatum strains.Entities:
Keywords: Corynebacterium striatum; multidrug resistant; multilocus sequence typing; nosocomial infections; opportunistic infections
Year: 2019 PMID: 30655682 PMCID: PMC6324608 DOI: 10.2147/IDR.S184518
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Figure 1Phylogenetic tree based on neighbor-joining method using 16S rRNA gene sequences.
Notes: Distance estimations were calculated using the Kimura two-parameter model. Bootstrap percentages after 1,000 simulations are shown. The Actinomyces bovis (T) X81061 sequence was used as an outgroup.
Demographic and basic characteristics of 67 patients whose clinical specimens tested positive for Corynebacterium striatum
| Variables | Total (N=67) | Treatment (n=20, 29.8%) | Observation (n=47, 70.1%) | |
|---|---|---|---|---|
|
| ||||
| Male, n (%) | 35 (52.2) | 14 (70.0) | 21 (44.7) | 0.058 |
| Age (years), median (IQR) | 64 (55–78) | 65 (59–75) | 69 (55–78) | 0.564 |
| Length from admission to | 15 (3–33) | 12 (0–25) | 20 (4–37) | 0.615 |
|
| ||||
| 0.975 | ||||
| Community onset | 13 (18.8) | 4 (20.0) | 9 (19.1) | |
| Hospital acquired | 6 (8.7) | 2 (1.0) | 4 (8.5) | |
| Nosocomial | 48 (71.6) | 14 (70.0) | 34 (72.3) | |
|
| ||||
| Cardiovascular | 22 (32.8) | 6 (30.0) | 16 (34.0) | 0.785 |
| Central nervous system | 29 (43.3) | 5 (25.0) | 24 (51.0) | 0.062 |
| Malignancy | 15 (22.4) | 5 (25.0) | 10 (21.3) | 0.756 |
| Renal | 4 (6.0) | 0 | 4 (8.5) | 0.309 |
| Hepatic | 5 (7.5) | 2 (10.0) | 3(6.4) | 0.631 |
| Respiratory | 1 (1.5) | 0 | 1 (2.1) | 1.000 |
| Hematology | 1 (1.5) | 0 | 1 (2.1) | 1.000 |
| Transplantation | 1 (1.5) | 0 | 1 (2.1) | 1.000 |
| Diabetes mellitus | 18 (26.9) | 7 (35.0) | 11 (23.4) | 0.374 |
| Charlson’s comorbidity index, median (IQR) | 2 (1–3) | 2 (0–3) | 2 (1–3) | 0.503 |
|
| ||||
| Recent admission | 54 (80.6) | 12 (60.0) | 42 (89.4) | 0.392 |
| Surgery | 24 (35.8) | 7 (35.0) | 17 (36.2) | 1.000 |
| Prior use of antibiotics, n (%) | 51 (76.1) | 14 (70.0) | 37 (78.7) | 0.534 |
| Steroid | 8 (11.9) | 3 (15.0) | 5 (10.6) | 0.687 |
| Foley catheter | 33 (49.3) | 8 (40.0) | 25 (53.2) | 0.425 |
| Mechanical ventilator | 27 (40.3) | 6 (30.0) | 21 (44.7) | 0.291 |
| ICU care | 23 (34.3) | 6 (30.0) | 17 (36.2) | 0.780 |
|
| ||||
| Fever, n (%) | 2 (3.0) | 0 | 2 (4.3) | 0.380 |
| WBC (×103/μL), median (IQR) | 9.8 (6.1–11.6) | 12.1 (6.3–13.2) | 8.9 (5.3–11.6) | 0.472 |
| CRP (mg/L), median (IQR) | 75 (15–130) | 109 (31–186) | 59 (9–104) | 0.437 |
| Procalcitonin (ng/mL), median (IQR) | 2.1 (0.1–2.9) | 1.7 (0.1–1.6) | 1.7 (0.1–1.6) | 0.484 |
Abbreviations: CRP, C-reactive protein; ICU, intensive care unit; WBC, white blood cell.
Microbiological characteristics and treatment outcomes of 67 patients whose clinical specimens tested positive for Corynebacterium striatum
| Parameters | Total (N=67) | Treatment (n=20, 29.8%) | Observation (n=47, 70.1%) | |
|---|---|---|---|---|
|
| ||||
| 0.005 | ||||
| Urine | 24 (35.8) | 2 (10.0) | 22 (46.8) | |
| Skin abscess | 22 (32.8) | 11 (55.0) | 11 (23.4) | |
| Otitis media | 10 (14.9) | 2 (10.0) | 8 (17.0) | |
| Blood | 6 (9.0) | 1 (5.0) | 5 (10.6) | |
| Ascites | 4 (6.0) | 3 (15.0) | 1 (2.1) | |
| Pleural effusion | 1 (1.5) | 1 (5.0) | 0 | |
|
| ||||
| 25 (38.8) | 13 (65.0) | 12 (25.5) | 0.003 | |
| 2 | 19 (76.0) | 9 (69.2) | 10 (83.3) | |
| ≥3 | 6 (24) | 4 (30.8 | 2 (16.7) | |
|
| ||||
| 5 (16.1) | 3 (17.6) | 2 (14.3) | 0.126 | |
| Carbapenem-resistant | 5 (16.1) | 4 (23.5) | 1 (7.1) | 0.011 |
| 5 (16.1) | 5 (29.4) | 0 | ||
| Methicillin-resistant | 3 (9.7) | 0 | 3 (21.4) | 0.248 |
| 3 (9.7) | 0 | 3 (21.4) | 0.248 | |
| Methicillin-susceptible | 2 (6.5) | 2 (11.8) | 0 | 0.028 |
| Methicillin-resistant coagulase-negative | 2 (6.5) | 0 | 2 (14.3) | 0.349 |
| 2 (6.5) | 1 (5.9) | 1 (7.1) | 0.527 | |
| 1 (3.2) | 1 (5.9) | 0 | 0.122 | |
| 1 (3.2) | 1 (5.9) | 0 | 0.122 | |
| 1 (3.2) | 0 | 1 (7.1) | 0.511 | |
| 1 (3.2) | 0 | 1 (7.1) | 0.511 | |
|
| ||||
| Penicillin | 2 (3.0) | 0 (0) | 2 (4.3) | 0.525 |
| Erythromycin | 67 (100) | 20 (100) | 47(100) | |
| Levofloxacin | 6 (9.0) | 3 (15.0) | 3 (6.4) | 0.845 |
| Vancomycin | 67 (100) | 20 (100) | 47(100) | |
| Linezolid | 67 (100) | 20 (100) | 47(100) | |
| Multidrug resistance, n (%) | 52 (77.6) | 14 (70.0) | 38 (80.9) | 0.106 |
|
| ||||
| In-hospital mortality, n (%) | 1 (1.5) | 1 (5.0) | 0 | 0.290 |
| Length of hospital stay since | 35 (5–77) | 31 (1–59) | 31 (1–59) | 0.695 |
MIC50 and MIC90 values and antimicrobial susceptibility (%) of the clinical isolates of Corynebacterium striatum
| Antibiotics | MIC (mg/L)
| Percentage of susceptible isolates | ||
|---|---|---|---|---|
| MIC50 | MIC90 | Range | ||
|
| ||||
| Penicillin | >4 | >4 | 0.12–>4 | 3.0 |
| Ampicillin | >4 | >4 | 0.25–4 | 6.0 |
| Cefotaxime | >2 | >2 | 1–>2 | 4.5 |
| Levofloxacin | >4 | >4 | ≤0.5–>4 | 9.0 |
| Erythromycin | >0.5 | >0.5 | ≤0.06–>0.5 | 100 |
| Linezolid | ≤1 | ≤1 | ≤1 | 100 |
| Vancomycin | 0.5 | 1 | ≤0.25–1 | 100 |
| Daptomycin | <0.25 | <0.25 | <0.25 | 100 |
Abbreviations: MIC, minimum inhibitory concentration; MIC50, MIC for inhibition of 50% of isolates tested; MIC90, MIC for inhibition of 90% of isolates tested.
Antimicrobial resistance patterns of 67 Corynebacterium striatum strains, categorized by susceptibility to penicillin, ampicillin, cefotaxime, levofloxacin, and vancomycin
| Resistance pattern (n) | Patients (n) | Antibiotics | |||||
|---|---|---|---|---|---|---|---|
| Inpatients | Outpatient | PEN | AMP | COF | LEV | VAN | |
| I (58) | 48 | 10 | R(I) | R(I) | R(I) | R(I) | S |
| II (5) | 1 | 4 | R(I) | R(I) | R(I) | S | S |
| III (2) | 1 | 1 | S | S | S | R(I) | S |
| IV (1) | 1 | 0 | R(I) | S | R(I) | R(I) | S |
| V (1) | 1 | 0 | R(I) | S | R(I) | S | S |
Abbreviations: AMP, ampicillin; COF, cefotaxime; I, intermediate; LEV, levofloxacin; PEN, penicillin; R, resistant; S, susceptible; VAN, vancomycin.
Figure 2The distribution of STs.
Abbreviation: ST, sequence type.
Primers used in the molecular analysis of 67 Corynebacterium striatum strains
| Gene | Primer | Sequence (5′→3′) | Function | Tª (°C) | Length (bp) | Reference |
|---|---|---|---|---|---|---|
|
| ||||||
| 16S rRNA | 16SF27 | AGAGTTTGATCMTGGCTCAG | 16S rDNA | 55 | 1,400 | |
| 16S rRNA (sequencing) | 16SF518 | CCAGCAGCCGCGGTAATAC | 16S rDNA | – | – | |
| ITS1 | 16F945 | GGGCCCGCACAAGCGGTGG | Interspacer sequence | 55 | 900 | |
| gyrA1 | GCGGCTACGTAAAGTCC | Gyrase | 55 | 400 | ||
| C2700F | CGWATGAACATYGGBCAGGT | β-subunit of RNA | 60 | 400 | ||
STs at three examined loci in the Corynebacterium striatum strain and patterns of antimicrobial resistance
| m | 16S rRNA | ITS1 | gyrA | rpoB | ST | Resistance pattern |
|---|---|---|---|---|---|---|
|
| ||||||
| 1 | 1 | 2 | 1 | 2 | 2 | I |
| 2 | 1 | 4 | 1 | 2 | 3 | I |
| 3 | 2 | 2 | 1 | 2 | 2 | II |
| 4 | 1 | 2 | 2 | 2 | 4 | I |
| 5 | 1 | 4 | 1 | 2 | 3 | I |
| 6 | 1 | 2 | 1 | 2 | 2 | I |
| 7 | 1 | 4 | 2 | 2 | 5 | II |
| 8 | 3 | 4 | 1 | 2 | 3 | I |
| 9 | 1 | 2 | 1 | 2 | 2 | I |
| 10 | 4 | 3 | 1 | 2 | 6 | I |
| 11 | 5 | 2 | 1 | 2 | 2 | I |
| 12 | 1 | 4 | 1 | 2 | 3 | I |
| 13 | 1 | 4 | 1 | 2 | 3 | I |
| 14 | 1 | 2 | 1 | 2 | 2 | I |
| 15 | 1 | 4 | 1 | 2 | 3 | I |
| 16 | 1 | 3 | 1 | 2 | 6 | I |
| 17 | 1 | 2 | 1 | 2 | 2 | I |
| 18 | 1 | 2 | 1 | 2 | 2 | I |
| 19 | 1 | 2 | 1 | 2 | 2 | I |
| 20 | 6 | 2 | 3 | 3 | 7 | II |
| 21 | 1 | 2 | 1 | 2 | 2 | I |
| 22 | 5 | 2 | 1 | 2 | 2 | I |
| 23 | 1 | 2 | 1 | 2 | 2 | I |
| 24 | 1 | 2 | 1 | 2 | 2 | I |
| 25 | 5 | 2 | 1 | 2 | 2 | I |
| 26 | 1 | 2 | 1 | 2 | 2 | I |
| 27 | 1 | 2 | 1 | 2 | 2 | I |
| 28 | 1 | 3 | 1 | 2 | 6 | I |
| 29 | 1 | 2 | 2 | 2 | 4 | I |
| 30 | 1 | 2 | 1 | 2 | 2 | I |
| 31 | 1 | 2 | 1 | 2 | 2 | I |
| 32 | 1 | 2 | 1 | 2 | 2 | I |
| 33 | 1 | 4 | 1 | 2 | 3 | I |
| 35 | 1 | 4 | 2 | 2 | 5 | II |
| 36 | 1 | 3 | 2 | 2 | 8 | I |
| 39 | 1 | 4 | 1 | 2 | 3 | I |
| 40 | 1 | 4 | 1 | 2 | 3 | II |
| 41 | 5 | 2 | 1 | 2 | 2 | I |
| 42 | 1 | 4 | 1 | 2 | 3 | I |
| 43 | 1 | 2 | 1 | 2 | 2 | I |
| 44 | 1 | 2 | 1 | 2 | 2 | I |
| 45 | 1 | 4 | 1 | 2 | 3 | I |
| 46 | 1 | 2 | 1 | 2 | 2 | V |
| 47 | 1 | 4 | 2 | 2 | 5 | III |
| 48 | 1 | 4 | 1 | 4 | 9 | III |
| 49 | 1 | 2 | 1 | 2 | 2 | I |
| 50 | 1 | 2 | 1 | 2 | 2 | I |
| 51 | 1 | 2 | 1 | 2 | 2 | I |
| 52 | 1 | 2 | 1 | 2 | 2 | I |
| 53 | 1 | 2 | 1 | 2 | 2 | I |
| 54 | 1 | 4 | 1 | 2 | 3 | I |
| 55 | 1 | 2 | 1 | 4 | 10 | I |
| 56 | 1 | 2 | 1 | 2 | 2 | I |
| 57 | 1 | 3 | 1 | 4 | 11 | I |
| 58 | 7 | 3 | 1 | 2 | 6 | I |
| 59 | 1 | 4 | 1 | 5 | 12 | I |
| 61 | 8 | 3 | 1 | 2 | 6 | I |
| 62 | 1 | 3 | 1 | 2 | 6 | I |
| 63 | 1 | 2 | 1 | 2 | 2 | I |
| 64 | 1 | 4 | 1 | 2 | 3 | IV |
| 65 | 1 | 3 | 1 | 2 | 6 | I |
| 66 | 1 | 3 | 1 | 2 | 6 | I |
| 67 | 1 | 3 | 1 | 2 | 6 | I |
| 69 | 9 | 3 | 1 | 2 | 6 | I |
| 70 | 1 | 4 | 1 | 2 | 3 | I |
| 71 | 1 | 2 | 1 | 6 | 13 | I |
| 72 | 1 | 4 | 1 | 2 | 3 | I |
| ATCC 6940 | 1 | 1 | 1 | 1 | 1 | |
Note:
Only three of the eight loci analyzed were taken into account in obtaining ST numbers (ITS1 region, gyrA, and rpoB genes).
Abbreviations: ITS1, internal transcribed spacer 1; ST, sequence type.